IL17A and amyloidosis: Helena et al. reported an accumulation of IL-17 in the brain, meninges and cervical lymph nodes of 3xTg-AD models at early stage of disease, while neutralizing IL-17 delayed the amyloidosis-related splenomegaly and short-memory deficits [30].